SYDNEY, Australia I July 14, 2025 I Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is pleased to ...

TSLP inhibitor Tezspire clinically has validated Thymic Stromal LymphoPoietin (TSLP) as a valid target for treatment of inflammatory diseases by its approval in late 2021 in the US and in 2022 in ...

OSAKA, Japan and CAMBRIDGE, MA, USA I July 14, 2025 I Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two ...

Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo ...

Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are resolvable ...

SAN DIEGO, CA, USA I July 11, 2025 I Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...

BASEL, Switzerland / MUNICH, Germany I July 10, 2025 I NUCLIDIUM, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Fully cell-free process aims to further democratize personalized cancer therapeutic manufacturing with shorter turnaround times and negligible bioburden and ...

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to ...

ROCKVILLE, MD, USA and SUZHOU, China I July 10, 2025 I Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing ...

AdventHealth Avista, an Orthopedic and Spine Center of Excellence, conducted the first lumbar fusion procedure with PearlMatrix Bone Graft, the first and only ...

New indication based on results of RATIONALE-309 study demonstrating statistically significant improvement in progression-free survival ...